Vismodegib, a SHH pathway inhibitor that binds SMO, was tested in pediatric and adult recurrent medulloblastomas, showing antitumor activity only in the SHH-subgroup of medulloblastomas [197]. This evidence concerns the gene SHH and medulloblastoma.